{"id":199855,"date":"2023-02-02T16:23:06","date_gmt":"2023-02-02T16:23:06","guid":{"rendered":"https:\/\/bioengineer.org\/duke-nus-and-nhcs-scientists-first-in-the-world-to-regenerate-diseased-kidney\/"},"modified":"2023-02-02T16:23:06","modified_gmt":"2023-02-02T16:23:06","slug":"duke-nus-and-nhcs-scientists-first-in-the-world-to-regenerate-diseased-kidney","status":"publish","type":"post","link":"https:\/\/bioengineer.org\/duke-nus-and-nhcs-scientists-first-in-the-world-to-regenerate-diseased-kidney\/","title":{"rendered":"Duke-NUS and NHCS scientists first in the world to regenerate diseased kidney"},"content":{"rendered":"

SINGAPORE, 1 February 2023<\/strong>\u00a0\u2013 In a world first, scientists at Duke-NUS Medical School, the National Heart Centre Singapore (NHCS) and colleagues in Germany have shown that regenerative therapy to restore impaired kidney function may soon be a possibility. In a preclinical study reported in\u00a0Nature Communications<\/em>, the team found that blocking a damaging and scar-regulating protein called interleukin-11 (IL-11) enables damaged kidney cells to regenerate, restoring impaired kidney function due to disease and acute injuries.<\/p>\n

\"Duke-NUS<\/p>\n

Credit: Duke-NUS Medical School<\/p>\n

<\/p>\n

\n

SINGAPORE, 1 February 2023<\/strong>\u00a0\u2013 In a world first, scientists at Duke-NUS Medical School, the National Heart Centre Singapore (NHCS) and colleagues in Germany have shown that regenerative therapy to restore impaired kidney function may soon be a possibility. In a preclinical study reported in\u00a0Nature Communications<\/em>, the team found that blocking a damaging and scar-regulating protein called interleukin-11 (IL-11) enables damaged kidney cells to regenerate, restoring impaired kidney function due to disease and acute injuries.<\/p>\n

\u201cKidney failure is a global epidemic,\u201d said Assistant Professor Anissa Widjaja, a molecular biologist with Duke-NUS\u2019\u00a0Cardiovascular & Metabolic Disorders (CVMD) Signature Research Programme. \u201cCloser to home, Singapore ranks first in the world for diabetes-induced kidney failure and fourth in terms of kidney failure prevalence. The contribution of chronic kidney disease to mortality is rapidly increasing, suggesting there are shortcomings in current therapeutic approaches.\u201d<\/p>\n

Searching for ways to restore the kidney\u2019s ability to regenerate damaged cells, Asst Prof Widjaja worked with\u00a0Professor Stuart Cook, Tanoto Foundation Professor of Cardiovascular Medicine at the SingHealth Duke-NUS Academic Medical Centre and the CVMD Programme, and Clinician Scientist and Senior Consultant with the Department of Cardiology, NHCS, and Duke-NUS\u00a0Dean Professor Thomas Coffman, a world-leading nephrologist. They teamed up with scientists in Germany to investigate the role of IL-11, which is known to trigger scarring in other organs, including the liver, lungs and heart, in acute and chronic kidney disease.<\/p>\n

Their findings implicate the protein in triggering a cascade of molecular processes in response to kidney injury that leads to inflammation, fibrosis (scarring) and loss of function. They also discovered that inhibiting IL-11 with a neutralising antibody can prevent and even reverse kidney damage in this setting.<\/p>\n

\u201cWe found that IL-11 is detrimental to kidney function and triggers the development of chronic kidney disease,\u201d said Professor Cook. \u201cWe also showed that anti-IL11 therapy can treat kidney failure, reverse established chronic kidney disease, and restore kidney function by promoting regeneration in mice, while being safe for long term use.\u201d<\/p>\n

More specifically, the researchers showed that renal tubular cells, which line the tiny tubes inside kidneys, release IL-11 in response to kidney damage. This turns on a signalling cascade that ultimately leads to increased expression of a gene, called Snail Family Transcriptional Repressor 1 (SNAI1), which arrests cellular growth and promotes kidney dysfunction.<\/p>\n

In a preclinical model of human diabetic kidney disease, turning off this process by administering an antibody that binds to IL-11 led to proliferation of the kidney tubule cells and reversal of fibrosis and inflammation, resulting in the regeneration of the injured kidney and the restoration of renal function.<\/p>\n

While clinical trials of an antibody that binds to another pro-fibrotic molecule called transforming growth factor beta have been unsuccessful, this new approach brings hope of a new target.<\/p>\n

\u201cBy boosting the kidney\u2019s intrinsic capability to regenerate, Prof Cook and Asst Prof Widjaja have shown that we can restore function to a damaged kidney,\u201d said Prof Coffman, who is also the principal investigator of the Diabetes Study in Nephropathy and other Microvascular Complications (DYNAMO), a large collaborative study that aims to find new solutions for the prevention and treatment of diabetic kidney disease. \u201cThis discovery could be a real game-changer in the treatment of chronic kidney disease\u2014which is a major public health concern in Singapore and globally\u2014bringing us one step closer to delivering the benefits promised by regenerative medicine.\u201d<\/p>\n

\n
\n
\n
\n
\n

Journal<\/h4>\n

Nature Communications<\/p>\n<\/p><\/div>\n

\n

DOI<\/h4>\n

10.1038\/s41467-022-35306-1 <\/i><\/p>\n<\/p><\/div>\n

\n

Method of Research<\/h4>\n

Experimental study<\/p>\n<\/p><\/div>\n

\n

Subject of Research<\/h4>\n

Animals<\/p>\n<\/p><\/div>\n

\n

Article Title<\/h4>\n

Targeting endogenous kidney regeneration using anti-IL11 therapy in acute and chronic models of kidney disease<\/p>\n<\/p><\/div>\n

\n

Article Publication Date<\/h4>\n

5-Dec-2022<\/p>\n<\/p><\/div>\n

\n

COI Statement<\/h4>\n

A.A.W., S.S., and S.A.C. are co-inventors of the US Patent 11339216 (Treatment of kidney injury). S.S. and S.A.C are co-inventors of the published patents: WO\/2017\/103108 (TREATMENT OF FIBROSIS), WO\/2018\/109174 (IL11 ANTIBODIES), WO\/2018\/109170 (IL11RA ANTIBODIES). S.S. and S.A.C. are co-founders and shareholders of Enleofen Bio PTE LTD, a company that made anti-IL11 therapeutics, which were acquired for further development by Boehringer Ingelheim in 2019. The remaining authors declare no competing interests.<\/p>\n<\/p><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"

SINGAPORE, 1 February 2023\u00a0\u2013 In a world first, scientists at Duke-NUS Medical School, the National Heart Centre Singapore (NHCS) and colleagues in Germany have shown that regenerative therapy to restore impaired kidney function may soon be a possibility. In a preclinical study reported in\u00a0Nature Communications, the team found that blocking a damaging and scar-regulating protein […]<\/p>\n","protected":false},"author":8,"featured_media":199856,"comment_status":"","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_override_bookmark_settings":[],"jnews_social_meta":[],"jnews_review":[],"enable_review":"","type":"","name":"","summary":"","brand":"","sku":"","good":[],"bad":[],"score_override":"","override_value":"","rating":[],"price":[],"jnews_override_counter":[],"footnotes":""},"categories":[231],"tags":[],"class_list":["post-199855","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer-science-news"],"_links":{"self":[{"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/posts\/199855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/comments?post=199855"}],"version-history":[{"count":0,"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/posts\/199855\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/media\/199856"}],"wp:attachment":[{"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/media?parent=199855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/categories?post=199855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bioengineer.org\/wp-json\/wp\/v2\/tags?post=199855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} BIOENGINEER.ORG

Wednesday, December 4, 2024
No Result
View All Result
No Result
View All Result
No Result
View All Result
Page 1 of 7687 1 2 … 7,687
No Result
View All Result

Bioengineer.org © Copyright 2023 All Rights Reserved.